About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Melanoma Clinical Trials in New York | 341 Studies | Clareo Health

Clinical Trials MelanomaNew York

Melanoma Clinical Trials in New York

Find 341 clinical trials for melanoma near New York, New York. Connect with research centers in your area.

All Melanoma trials nationwide All trials in New York

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 141-160 of 341 trials

Active Not RecruitingPhase 1< 1 mile

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pancreatic CancerBreast CancerGastric Cancer+13 more

NGM Biopharmaceuticals, Inc130 participantsStarted Mar 2022

Gilbert, Arizona, United States • Los Angeles, California, United States • Sarasota, Florida, United States +6 more locations

COMPLETEDPhase 2< 1 mile

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

NCT00378482

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Colorectal NeoplasmsMelanomaProstatic Neoplasms+3 more

AstraZeneca37 participantsStarted Mar 2007

Los Angeles, California, United States • Tampa, Florida, United States • Ann Arbor, Michigan, United States +3 more locations

Melanoma Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

COMPLETEDPhase 1< 1 mile

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866

This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more

National Cancer Institute (NCI)58 participantsStarted Apr 2016

Birmingham, Alabama, United States • San Francisco, California, United States • San Francisco, California, United States +9 more locations

COMPLETEDPhase 2< 1 mile

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672

The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.

Memorial Sloan Kettering Cancer Center7 participantsStarted Jul 2013

Basking Ridge, New Jersey, United States • Commack, New York, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 1< 1 mile

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more

Xencor, Inc.198 participantsStarted May 2019

San Diego, California, United States • Aurora, Colorado, United States • Denver, Colorado, United States +15 more locations

COMPLETEDPhase 2< 1 mile

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

NCT02970981

The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.

NYU Langone Health18 participantsStarted Nov 2016

New York, New York, United States

COMPLETEDPhase 1< 1 mile

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

Advanced MelanomaMetastatic Melanoma

Bristol-Myers Squibb170 participantsStarted Sep 2012

Los Angeles, California, United States • Chicago, Illinois, United States • Lutherville, Maryland, United States +11 more locations

TERMINATEDPhase 1< 1 mile

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 \[PD-1\] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more

Pfizer13 participantsStarted Oct 2021

Duarte, California, United States • New York, New York, United States • New York, New York, United States

COMPLETEDPhase 2< 1 mile

Neoadjuvant and Adjuvant Checkpoint Blockade

NCT02519322

This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, and relatlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab alone or in combination with ipilimumab or relatlimab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Cutaneous MelanomaMucosal MelanomaOcular Melanoma+8 more

M.D. Anderson Cancer Center53 participantsStarted Feb 2016

New York, New York, United States • Houston, Texas, United States

Active Not RecruitingPhase 1/23.3 miles

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

NCT05060432

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.

Advanced CancerLung CancerHead and Neck Cancer+1 more

iTeos Belgium SA153 participantsStarted Sep 2021

San Diego, California, United States • Bergen, New Jersey, United States • Antwerp, Antwerp, Belgium +39 more locations

TERMINATEDPhase 228 miles

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

NCT04152863

This is a Phase 2 study to assess the efficacy, safety, and tolerability of gebasaxturev administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone in anti-programmed cell death ligand 1 (anti-PD-L1)-treatment-naive participants with advanced/metastatic melanoma. The primary hypothesis of the study is that gebasaxturev administered either ITu or IV in combination with pembrolizumab results in a superior objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR), compared to pembrolizumab alone. This study will be terminated once all participants finish treatment with V937. Participants eligible to continue to receive pembrolizumab will be transferred to MK-3475-587 study.

Advanced/Metastatic Melanoma

Merck Sharp & Dohme LLC85 participantsStarted Jun 2020

Detroit, Michigan, United States • New Brunswick, New Jersey, United States • Portland, Oregon, United States +27 more locations

COMPLETEDPhase 170 miles

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

NCT03875079

This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1. and 1.2) and two expansion parts (Parts II and III). Part II will start once all participants in Cohort 1.1 have completed the observation period. Part III will start once all participants in Cohorts 1.1 and 1.2 have completed the observation period.

Metastatic Melanoma

Hoffmann-La Roche83 participantsStarted Jun 2019

New Haven, Connecticut, United States • Iowa City, Iowa, United States • Boston, Massachusetts, United States +20 more locations

TERMINATEDPhase 170 miles

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

Active Not RecruitingPhase 1/2135 miles

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

MesotheliomaGlioblastomaRenal Cell Carcinoma+12 more

NGM Biopharmaceuticals, Inc179 participantsStarted Jun 2021

Los Angeles, California, United States • Newport Beach, California, United States • Santa Monica, California, United States +24 more locations

COMPLETEDPhase 1190 miles

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

NCT04160065

In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and/or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design).

Merkel Cell CarcinomaCutaneous Squamous Cell CarcinomaNon-Melanoma Skin Cancers

TuHURA Biosciences, Inc.23 participantsStarted Mar 2020

Los Angeles, California, United States • Tampa, Florida, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 2218 miles

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

NCT03776136

This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy in adult participants with unresectable or advanced melanoma who have been exposed to anti-programmed cell death ligand 1 (PD-1/L1) agents approved for unresectable or metastatic melanoma. No statistical hypothesis will be tested in this study.

Advanced Melanoma

Merck Sharp & Dohme LLC103 participantsStarted Jan 2019

Chandler, Arizona, United States • Santa Monica, California, United States • Park Ridge, Illinois, United States +20 more locations

COMPLETEDPhase 1332 miles

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

NCT03864042

This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme probe substrates using a probe cocktail, on an organic anion-transporting polypeptide/breast cancer resistance protein (OATP/BCRP) substrate using rosuvastatin and on a CYP2B6 substrate using bupropion. The effect of multiple oral doses of the moderate cytochrome P450 (CYP) inhibitor modafinil on encorafenib in combination with binimetinib will also be assessed. The study will have 2 treatment phases, a drug-drug interaction (DDI) phase followed by a post-DDI phase.

Advanced Solid TumorsMetastatic Melanoma

Pfizer56 participantsStarted Jan 2018

Orange, California, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +26 more locations

COMPLETEDPhase 1345 miles

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Solid TumorMicrosatellite Instability-High (MSI-H) Solid TumorsCutaneous Melanoma+2 more

Eli Lilly and Company164 participantsStarted Jun 2016

Nashville, Tennessee, United States • Houston, Texas, United States • San Antonio, Texas, United States +11 more locations

TERMINATEDPhase 1/2481 miles

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

NCT04198818

This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.

Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more

Haihe Biopharma Co., Ltd.37 participantsStarted Jan 2020

Lafayette, Indiana, United States • Detroit, Michigan, United States • Shanghai, China

COMPLETEDPhase 1/21417 miles

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

NCT04123470

This study aims to evaluate safety and effect of combining an oncolytic adenovirus (delolimogene mupadenorepvec; LOAd703) with atezolizumab in patients with melanoma. LOAd703 will be administered intratumorally for up to 12 injections while atezolizumab will be administered intravenously for the duration of the active study visits (up to 57 weeks). The patients are then monitored for survival for maximum study participation of 48 months. The treatments will be given every 3 weeks. The patients will then be monitored for toxicity, PK, ADA, immune responses, virus shedding, tumor response by RECIST 1.1 and survival.

Malignant Melanoma

Lokon Pharma AB24 participantsStarted Jan 2020

Los Angeles, California, United States • Houston, Texas, United States • Uppsala, Sweden

PreviousPage 8 of 18Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma